An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT00488631 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1228

Enrollment

INDUSTRY

Sponsor class

Conditions

Colitis, Ulcerative

Interventions

BIOLOGICAL: Placebo
BIOLOGICAL: Golimumab 50 mg
BIOLOGICAL: Golimumab 100 mg
BIOLOGICAL: Golimumab 200 mg

Sponsor

Janssen Research & Development, LLC

Collaborators

[object Object]